Industry

TORONTO & DALLAS–(BUSINESS WIRE)–$PINK.V #AI–Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTC: PYNKF) (FSE: 4PC) (“Perimeter” or the “Company”) – a medical technology company driven to transform cancer surgery with ultra-high-resolution, real-time, advanced imaging tools to address high unmet medical needs, announced the results of its 2022 annual and special meeting of shareholders (the “Meeting”) … [Read more…]

SAN DIEGO–(BUSINESS WIRE)–Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global, late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that the Company will present at the following investor conferences. Guggenheim 4th Annual Immunology and Neurology Day … [Read more…]

Q3 Revenue of $104.3 Million Up 22% Year-Over-Year; Company Raises Full-Year 2022 Revenue and Adjusted EBITDA Guidance Co-founder and CEO Stan Vashovsky announces his retirement effective December 31st; DocGo President Anthony Capone named new CEO; Mr. Vashovsky will consult with the Company through 2023 to assist with the transition Company to host investor conference call … [Read more…]

Net sales in the first quarter of fiscal 2023 totaled $405.9 million, an all-time quarterly high and up 39% year-over-year; foreign currency had a 5% unfavorable impact on net sales compared to the first quarter of fiscal 2022 Operating income of $13.6 million, or 3.3% of net sales, compared to operating income of $4.8 million, … [Read more…]

Findings from the first clinical trial program comparing the use of Teva’s Digihaler® System to standard of care in asthma management will be presented across six abstracts TEL AVIV, Israel & PARSIPPANY, N.J.–(BUSINESS WIRE)–Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new findings from … [Read more…]

BILLERICA, Mass.–(BUSINESS WIRE)–$BRKR #BRKR—Bruker Corporation (Nasdaq: BRKR) announced today it will participate in the 2022 Jefferies London Healthcare Conference. Gerald Herman, Executive Vice President & Chief Financial Officer will present and participate in an analyst moderated question and answer session on behalf of the Company on Tuesday, November 15, 2022 at 12:00 PM Eastern Time. … [Read more…]

Announced Positive Interim Data from the U.S.-based Phase 1 Clinical Trial of OTX-TKI for the Treatment of Wet AMD at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting Initiation of OTX-TKI Phase 1 Clinical Trial for the treatment of Diabetic Retinopathy Planned for Q1 of 2023 and Phase 2/3 Clinical Trial for the treatment … [Read more…]

— XmAb564, engineered IL-2 cytokine, is well-tolerated and generates a durable, dose-dependent and selective expansion of Tregs in single-dose, healthy volunteer study — — Management to host conference call at 4:30 p.m. ET Today — MONROVIA, Calif.–(BUSINESS WIRE)–Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and … [Read more…]

— Durable, dose-dependent and selective expansion of CD25bright Tregs, reaching a 117-fold increase over baseline at the highest dose — — Single dose of XmAb564 well-tolerated with no reported serious adverse events — — First patient dosed in Phase 1b, multiple-ascending dose study in patients with atopic dermatitis or psoriasis — — Phase 1a results … [Read more…]

MINNEAPOLIS–(BUSINESS WIRE)–FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that it will report financial results for the third quarter ended September 30, 2022 after market closes on Monday, November 14, 2022. Management will … [Read more…]